EAI-045
EAI-045 Basic information
- Product Name:
- EAI-045
- Synonyms:
-
- EAI-045
- 2-(5-fluoro-2-hydroxyphenyl)-2-(1-oxoisoindolin-2-yl)-N-(thiazol-2-yl)acetamide
- EA1045
- α-(5-fluoro-2-hydroxyphenyl)-1,3-dihydro-1-oxo-N-2-thiazolyl-2H-Isoindole-2-acetamide
- EAI 045;EAI-045
- CS-2350
- EAI045;EAI 045;EAI-045
- N-(3-((5-fluoroethoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide (EAI-045)
- CAS:
- 1942114-09-1
- MF:
- C19H14FN3O3S
- MW:
- 383.4
- Product Categories:
-
- API
- API
- Mol File:
- 1942114-09-1.mol
EAI-045 Chemical Properties
- Density
- 1.546±0.06 g/cm3(Predicted)
- storage temp.
- 2-8°C
- solubility
- ≥38.3 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
- form
- solid
- pka
- 7.20±0.50(Predicted)
- color
- White to khaki
EAI-045 Usage And Synthesis
Description
EAI045 is a potent and selective inhibitor of mutant EGF receptors (EGFRs; IC50s = 0.076, 0.049, 0.002, and 1.6 μM for recombinant EGFRL858R, EGFRT790M, EGFRL858R/T790M, and wild-type EGFR, respectively). It inhibits phosphorylation of EGFR in a concentration-dependent manner in H1975 cells. EAI045 (0.01-10 μM) reduces proliferation of Ba/F3 cells expressing EGFRL858R/T790M and EGFRL858R/T790M/I941R. In vivo, EAI045 induces tumor regression and reduces EGFR signaling in mice bearing EGFRL858R/T790M, EGFRExon19del/T790M, and EGFRL858R/T790M/C797S tumors when administered at a dose of 60 mg/kg per day in combination with cetuximab.
Description
EAI045 is a potent and selective EGFR inhibitor (fourth generation). EAI045 targets selected drug-resistant EGFR mutants without affecting the wild-type receptor. EAI045 inhibits L858R/T790M-mutant EGFR with low-nanomolar potency in biochemical assays. Therefore, it is a potential candidate drug for the treatment of related non-small cell lung cancer (NSCLC). It should be noted that EAI-045 is effectively in targeting the EGFR C797S mutation, which is resistance to the third-generation EGFR inhibitors including AZD9291 (osimertinib) and CO-1686 (rociletinib).
Uses
Epidermal growth factor receptor (EGFR) is a cell surface receptor often mutated in cancer cells. α-?(5-Fluoro-?2-?hydroxyphenyl)?-?1,?3-?dihydro-?1-?oxo-?N-?2-?thiazolyl-2H-?isoindole-?2-?acetamide is an allosteric EGFR inhibitor that is selective against drug-resistant EGFR mutants.
References
Wang, S., Y. Song, and D. Liu. "EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance." Cancer Letters385(2017):51.
Jia, Y., et al. "Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors:." Nature 534.7605(2016):129.
EAI-045Supplier
- Tel
- 18908622922
- 3464928989@qq.com
- Tel
- 18164232327
- 2709603029@qq.com
- Tel
- sales@boylechem.com
- Tel
- 0411-62910999 13889544652
- meilunui@163.com
- Tel
- 021-58950125
- info@chemexpress.com